患者内16α-[18F]氟-17β-雌二醇PET异质性作为雌激素受体阳性转移性乳腺癌内分泌治疗反应与生存的预后因素
在IMPACT-MBC研究的事后回顾性子分析中,102例雌激素受体(ER)阳性转移性乳腺癌(MBC)患者接受基线[18F]FES PET和[18F]FDG PET及一线内分泌治疗,比较ER同质性与异质性MBC的生存及两种简化评估方法的预测价值。
要点
- ER同质性MBC患者中位无进展生存期19.8个月 vs 异质性15.0个月(HR 0.63,95%CI 0.41-0.96,P=0.03)。
- ER同质性MBC患者中位总生存期62.5个月 vs 异质性34.7个月(HR 0.65,95%CI 0.38-1.08,P=0.09)。
- 视觉评估和5个最大病灶法预测同质性MBC的阳性预测值分别为0.66和0.55。
核心结论
- ER阳性同质性MBC患者较ER异质性MBC患者显示出更优的无进展生存期和总生存期趋势。
- 本分析在大型MBC队列中证实并验证了[18F]FES PET异质性评分对内分泌治疗反应和生存的预后价值。
- 基于全部病灶[18F]FES PET异质性评分的评估优于两种简化方法。
研究设计与样本
- IMPACT-MBC研究的事后回顾性子分析,纳入102例接受基线[18F]FES PET和[18F]FDG PET及一线内分泌治疗的ER阳性MBC患者。
- 通过[18F]FES PET全部病灶手动分割区分ER同质性(100% [18F]FES阳性病灶)与ER异质性(同时存在[18F]FES阳性和阴性病灶)MBC。
- 评估视觉评估和5个最大病灶法预测全部病灶[18F]FES PET同质性MBC的阳性预测值。
主要发现
- 102例可评估患者中,46例为ER同质性MBC,56例为ER异质性MBC。
- ER同质性 vs 异质性MBC的中位无进展生存期:19.8个月 vs 15.0个月(HR 0.63,95%CI 0.41-0.96,P=0.03)。
- ER同质性 vs 异质性MBC的中位总生存期:62.5个月 vs 34.7个月(HR 0.65,95%CI 0.38-1.08,P=0.09)。
- 视觉评估判定为ER同质性MBC的61例患者中,21例(38%)经全部病灶手动分割实为ER异质性MBC,阳性预测值为0.66。
- 5个最大病灶法判定为ER同质性MBC的83例患者中,37例(45%)经全部病灶手动分割实为ER异质性MBC,阳性预测值为0.55。
关键数值与推荐
- ER同质性MBC定义为全部病灶均为[18F]FES阳性(100%)。
- ER异质性MBC定义为同时存在[18F]FES阳性和[18F]FES阴性病灶。
- 视觉评估预测全部病灶同质性MBC的阳性预测值为0.66。
- 5个最大病灶法预测全部病灶同质性MBC的阳性预测值为0.55。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本分析为回顾性子分析。
- 总生存期比较的95%CI为0.38-1.08,跨1,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intrapatient heterogeneity of estrogen receptor (ER) expression on 16α-[18F]fluoro-17β-estradiol ([18F]FES) PET is related to outcome in patients with ER-positive metastatic breast cancer (MBC), but a validated and practical method to support clinical decision-making is lacking. Therefore, the [18F]FES PET heterogeneity score (i.e., percentage of [18F]FES-positive metastases) was validated as a prognostic factor for endocrine therapy response and survival in a large cohort of patients with newly diagnosed MBC. Furthermore, we explored 2 less laborious methods to predict the [18F]FES PET heterogeneity score. Methods: Patients with ER-positive MBC included in the IMPACT-MBC study, who received baseline [18F]FES and [18F]FDG PET and first-line endocrine therapy, were included in this subanalysis. ER homogeneous (100% [18F]FES-positive lesions) and ER heterogeneous (both [18F]FES-positive and [18F]FES-negative lesions) MBC was distinguished by manual segmentation of all lesions on [18F]FES PET and related to progression-free survival (PFS) and overall survival (OS). In addition, the positive predictive value of the visual assessment and the 5-largest-lesions assessment to predict homogeneous MBC in all lesions on [18F]FES PET was determined. Results: From the 102 MBC patients eligible for the present retrospective subanalysis, 46 had ER homogeneous MBC and 56 had ER heterogeneous MBC. Differences were found between ER homogeneous and ER heterogeneous MBC for median PFS (19.8 vs. 15.0 mo; hazard ratio, 0.63; 95% CI, 0.41-0.96; P = 0.03) and median OS (62.5 vs. 34.7 mo; hazard ratio, 0.65; 95% CI, 0.38-1.08; P = 0.09). Twenty-one (38%) of 61 patients with ER homogeneous MBC by visual analysis and 37 (45%) of 83 patients with ER homogeneous MBC by the 5-largest-lesions method had ER heterogeneous MBC by manual segmentation of all lesions on [18F]FES PET (positive predictive value, 0.66 and 0.55, respectively). Conclusion: Patients with ER-positive homogeneous MBC showed a trend toward superior PFS and OS compared with patients with ER heterogeneous MBC. This analysis confirmed and validated the prognostic value of the [18F]FES PET heterogeneity score for endocrine therapy response and survival in a large cohort of MBC patients. The less laborious visual and 5-largest-lesions methods were inferior compared with assessment based on the [18F]FES PET heterogeneity score in all lesions.
引用
- van Geel JJL, Moustaquim J, Boers J, et al. Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. J Nucl Med. 2025. PMID: 39848768. doi:10.2967/jnumed.124.268984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。